Clinical significance of troponin I efflux and troponin autoantibodies in patients with dilated cardiomyopathy
- PMID: 18672196
- DOI: 10.1016/j.cardfail.2008.02.009
Clinical significance of troponin I efflux and troponin autoantibodies in patients with dilated cardiomyopathy
Abstract
Background: The appearance of circulating autoantibodies against cardiac troponin I (cTnAbs) in patients with heart failure has been reported. We sought to evaluate the role of circulating cardiac troponin I (cTnI) and cTnAbs in the pathophysiology and prognosis of idiopathic dilated cardiomyopathy.
Methods and results: Circulating concentrations of cTnI and the presence of cTnAbs were determined in 95 patients with idiopathic dilated cardiomyopathy. The patients underwent laboratory testing, echocardiography, cardiopulmonary exercise testing, gated single photon emission computed tomography, and both-sided cardiac catheterization during a 3-day study period. Compared with cTnI- patients, the hearts of cTnI+ patients (cTnI > or = 0.01 ng/mL, n = 19) were significantly more dilated (left ventricular end-diastolic diameter 67 vs 61 mm, P < .05; left ventricular end-systolic dimension, 55 vs 49 mm, P < .01; echocardiography) and demonstrated greater intracardiac volumes (left ventricular end-diastolic volume 161 vs 132 mL, P = .060; left ventricular end-systolic volume 112 vs 82 mL, P < .05; gated single photon emission computed tomography), more disturbed systolic (ejection fraction 27 vs 33%, P < .05; gated single photon emission computed tomography) and cardiac sympathetic (123I-metaiodobenzylguanidine washout: 41% vs 34%; P < .05) function, and higher levels of vasoactive peptides (N-terminal proatrial natriuretic peptide 1030 vs 558 pmol/L, P < .05; N-terminal pro-B type natriuretic peptide 337 vs 115 pmol/L, P < .05). In addition, during a median follow-up time of 4.1 years, cTnI+ patients had clinical end points (cardiovascular death, heart transplantation, or clinical need for an automatic implantable cardioverter defibrillator) more often than cTnI- patients (37% vs 8%, P < .01). The presence of circulating cTnAbs (n = 15) was not associated with patients' clinical status or outcome.
Conclusion: Patients with idiopathic dilated cardiomyopathy with cTnI efflux demonstrate more prominent changes in the indices of left ventricular remodeling and function than patients without signs of cTnI efflux. Moreover, elevated serum cTnI is associated with poor clinical outcome. The presence of circulating cTnAbs seems to have less utility in the clinical assessment of these patients. However, their pathogenic role in disease progression in the long term cannot be excluded.
Similar articles
-
Changes in natriuretic peptides following passive containment surgery in heart failure patients with dilated cardiomyopathy.Interact Cardiovasc Thorac Surg. 2009 Feb;8(2):191-4. doi: 10.1510/icvts.2008.186296. Epub 2008 Nov 13. Interact Cardiovasc Thorac Surg. 2009. PMID: 19008326
-
Reversed remodelling in dilated cardiomyopathy by passive containment surgery is associated with decreased circulating levels of endothelin-1.Eur J Cardiothorac Surg. 2006 Mar;29(3):299-303. doi: 10.1016/j.ejcts.2005.12.011. Epub 2006 Jan 26. Eur J Cardiothorac Surg. 2006. PMID: 16442807
-
Absence of auto-antibodies against cardiac troponin I predicts improvement of left ventricular function after acute myocardial infarction.Eur Heart J. 2008 Aug;29(16):1949-55. doi: 10.1093/eurheartj/ehn268. Epub 2008 Jun 13. Eur Heart J. 2008. PMID: 18556712
-
Pathogenic roles of cardiac autoantibodies in dilated cardiomyopathy.Trends Mol Med. 2005 Jul;11(7):322-6. doi: 10.1016/j.molmed.2005.05.001. Trends Mol Med. 2005. PMID: 15935731 Review.
-
Prevalence of elevated troponin I in end-stage renal disease patients receiving hemodialysis.Acad Emerg Med. 2004 Sep;11(9):979-81. doi: 10.1197/j.aem.2004.03.022. Acad Emerg Med. 2004. PMID: 15347551 Review.
Cited by
-
Troponin and anti-troponin autoantibody levels in patients with ventricular noncompaction.PLoS One. 2013;8(2):e57648. doi: 10.1371/journal.pone.0057648. Epub 2013 Feb 28. PLoS One. 2013. PMID: 23469039 Free PMC article.
-
β1 Adrenergic Receptor Autoantibodies and IgG Subclasses: Current Status and Unsolved Issues.J Cardiovasc Dev Dis. 2023 Sep 10;10(9):390. doi: 10.3390/jcdd10090390. J Cardiovasc Dev Dis. 2023. PMID: 37754819 Free PMC article. Review.
-
Autoimmunity in Cardiomyopathy-Induced Heart Failure and Cardiac Autoantibody Removal by Immunoadsorption.J Clin Med. 2025 Feb 1;14(3):947. doi: 10.3390/jcm14030947. J Clin Med. 2025. PMID: 39941618 Free PMC article. Review.
-
Autoantibodies and cardiovascular dysfunction: cause or consequence?Curr Heart Fail Rep. 2014 Dec;11(4):500-8. doi: 10.1007/s11897-014-0217-5. Curr Heart Fail Rep. 2014. PMID: 25142807 Free PMC article. Review.
-
The diagnostic and clinical significance of anti-muscarinic receptor autoantibodies.Clin Rev Allergy Immunol. 2012 Jun;42(3):298-308. doi: 10.1007/s12016-010-8235-x. Clin Rev Allergy Immunol. 2012. PMID: 21207192 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials